Ligand is developing a Captisol-enabled™ injectable formulation of the antihistamine cetirizine to provide rapid onset to treat acute, life-threatening, allergy symptoms. In the hospital setting, this product is designed to address need for an injectable antihistamine to treat acute allergic reactions in emergency departments where oral administration is ineffective due to slow and untrustworthy absorption and ability to treat patients incapable of taking an oral medication. In addition, this formulation may be further concentrated and suitable for self-administered injection or via a “pen”.
